Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Other Operating Expenses (2016 - 2026)

Heron Therapeutics filings provide 13 years of Other Operating Expenses readings, the most recent being $14.3 million for Q1 2026.

  • On a quarterly basis, Other Operating Expenses rose 16.22% to $14.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $51.1 million, a 6.47% increase, with the full-year FY2025 number at $49.1 million, up 4.2% from a year prior.
  • Other Operating Expenses hit $14.3 million in Q1 2026 for Heron Therapeutics, up from $12.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $39.1 million in Q2 2022 to a low of $11.0 million in Q3 2024.
  • Median Other Operating Expenses over the past 5 years was $13.0 million (2023), compared with a mean of $16.9 million.
  • The widest YoY moves for Other Operating Expenses: up 42.28% in 2022, down 49.83% in 2022.
  • Heron Therapeutics' Other Operating Expenses stood at $17.8 million in 2022, then plummeted by 30.64% to $12.3 million in 2023, then fell by 10.31% to $11.1 million in 2024, then rose by 10.64% to $12.2 million in 2025, then increased by 16.96% to $14.3 million in 2026.
  • The last three reported values for Other Operating Expenses were $14.3 million (Q1 2026), $12.2 million (Q4 2025), and $12.9 million (Q3 2025) per Business Quant data.